US 2010/0168174 A1 · Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain

Abstract

The invention provides methods for treating and/or preventing neuropathic pain by administering to patients in need thereof therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The neuropathic pain may be painful diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine (donepezil).

Claims22

Dependent claims

A pharmaceutical composition comprising:

(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof;
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof;
an anti-neuropathic pain agent;
or a mixture or combination thereof;
and
(C) one or more pharmaceutically acceptable carriers.

3 more elements

A combination comprising:

(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof;
and
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof;
an anti-neuropathic pain agent;
or a mixture or combination thereof.

2 more elements

Use of compounds (A) and (B) for producing a pharmaceutical composition in the treatment of neuropathic pain, wherein (A) and (B) are:

(A) an AMPA receptor antagonist, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a hydrate of a pharmaceutically acceptable salt thereof;
and
(B) a cholinesterase inhibitor or a pharmaceutically acceptable salt thereof;
an anti-neuropathic pain agent;
or a mixture or combination thereof.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

12/663,550Filed 11 Jul 2008

Priority

13 Jul 2007

Published

1 Jul 2010

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

A61K 31/44
Having six-membered rings with one nitrogen as the only ring hetero atom: non condensed pyridines; Hydrogenated derivatives thereof
A61K 31/27
Esters, e.g. nitroglycerine, selenocyanates: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
A61K 31/55
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 25/00
Drugs for disorders of the nervous system

Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain

Life of this patent

Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain

Life of this patent

Abstract

Claims22